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Background: Evidence indicates that CYP1A1 MspI polymorphism might be a possible risk factor for several
malignancies. A growing body of literature has been devoted to the association of CYP1A1 MspI polymorphism
with acute myeloid leukemia (AML). However, the results remain conflicting. The aim of the present study was to
derive a more precise estimation of the relationship.
Methods: Meta-analyses assessing the association of CYP1A1 MspI variation with AML were conducted and
subgroup analyses on ethnicity and age groups were further performed. Eligible studies were identified for the
period up to May 2012.
Results: A total of ten case–control studies including 1330 cases and 3688 controls were selected for analysis. The
overall data failed to indicate a significant association of CYP1A1 MspI polymorphism with AML risk (C vs T:
OR = 1.13; 95%CI = 0.87-1.48; CC vs TT: OR = 1.72; 95%CI = 0.99-3.01; CC + TC vs TT: OR = 1.16; 95%CI = 0.86-1.55). In
subgroup analysis stratified by ethnicity, significant AML risk was shown among Asians (CC + TC vs TT: OR = 1.33;
95%CI = 1.09-1.62) but not Caucasians or mixed races. In subgroup analysis regarding age groups, no associations
were observed in either the childhood AML or the adult AML subgroups.
Conclusion: The results of the present study suggested that CYP1A1 MspI polymorphism might be a risk factor for
AML among Asians. Further investigations are needed to confirm the conclusions.
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Acute myeloid leukemia (AML), also known as acute
nonlymphocytic leukemia (ANLL), is the most common
acute leukemia mostly affecting adults, characterized by
the rapid growth of abnormal white blood cells in the
bone marrow and impaired production of normal blood
cells. The mechanisms for AML genesis are still rarely
understood. Evidence suggests that radiation, smoking,
obesity and exposure to chemical carcinogens are con-
sidered as its possible risk factors [1]. Nevertheless,
AML only develops in a small proportion of people
exposed to these environmental and lifestyle risk factors,* Correspondence: zhuowenlei@yahoo.com.cn
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reproduction in any medium, provided the orindicating that the host genetic background might play a
critical role in its genesis.
Several genetic polymorphisms have been determined
as possible risk factors for leukemia by meta-analyses.
Variations of GSTM1, GSTT1, MTHFR C677T and
XRCC1 Arg399Gln have been indicated to raise leukemia
susceptibility [2-4]. Nevertheless, polymorphic MTR
A2756G has been shown to decrease acute leukemia risk
[5]. Therefore, different genetic polymorphisms might
exert different effects on leukemia risk. Nevertheless,
only a few gene polymorphisms associated with leukemia
susceptibility have been identified to date.
Recent evidence indicates that carcinogen-metabolizing
genes might play critical roles in determining individual
susceptibility to cancers [6]. Susceptibility to cancer is
determined by the activation of enzymes involved in
carcinogen activation or deactivation. Polymorphisms intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zhuo et al. Journal of Experimental & Clinical Cancer Research 2012, 31:62 Page 2 of 10
http://www.jeccr.com/content/31/1/62these genes encoding the enzymes, possibly by altering
their functions, might increase or decrease carcinogen
activation/detoxification and modulate DNA repair pro-
cess. Cytochrome P450 (CYP) enzymes catalyze Phase I
metabolism reaction. Cytochrome P450 1A1 (CYP1A1)
is a member of the CYP family that participates in
the metabolism of xenobiotics and endogenous com-
pounds, particularly polycyclic aromatic hydrocarbons
(PAHs) such as benzo[a]pyrene in smoke [7]. A com-
monly studied single nucleotide polymorphism (SNP)
in the CYP1A1 gene has been indicated to associate
with cancer susceptibility. The SNP locates at nucleo-
tide 3801 in the 3’ non-coding region containing a single
T to C base substitution that results in a polymor-
phic restriction site for the MspI enzyme (MspI or
CYP1A1*2A polymorphism, rs4646903). The MspI restric-
tion site polymorphism results in three genotypes: a
predominant homozygous m1 allele without the MspI
site (type A, TT), the heterozygote (type B, TC) and a
homozygous rare m2 allele with the MspI site (type C,
CC) [8].
Published studies devoted to the relationship between
CYP1A1 MspI polymorphism and AML risk have gener-
ated controversial results. The issue of whether CYP1A1
MspI polymorphism is a risk factor for AML remains
uncertain. Therefore, in this study, we aimed to perform
a quantitative meta-analysis that increased statistical
power to generate more confidential results.Figure 1 The flow diagram of included/excluded studies.Materials and methods
Literature search strategy
We carried out a search in the Medline, EMBASE,
OVID, Sciencedirect, and Chinese National Knowledge
Infrastructure (CNKI) without a language limitation,
covering all publications published up to May 2012,
with a combination of the following keywords: Cyto-
chrome P450 1A1, CYP1A1, T3801C, MspI, acute myeloid
leukemia, acute nonlymphocytic leukemia, hematology,
malignancy, neoplasm, cancer, variation and polymorph-
ism. All searched studies were retrieved and the bibliog-
raphies were checked for other relevant publications.
Review articles and bibliographies of other relevant stud-
ies identified were hand searched to find additional eli-
gible studies.
Inclusion and exclusion criteria
The following criteria were used for the literature selec-
tion: first, studies should concern the association of
CYP1A1 MspI polymorphism with AML risk; second,
studies must be observational studies (Case—control or
cohort); third, papers must offer the size of the sample,
odds ratios (ORs) and their 95% confidence intervals
(CIs), the genetic distribution or the information that
can help infer the results. Accordingly, the following cri-
teria for exclusion were also utilized: first, the design
and the definition of the experiments were obviously
different from those of the selected articles; second, the














Balta 2003 33 (19/14) 185 (120/65) 33 AML Healthy controls (PB) 8.7(1–17)/7.4(0.58-17) Mixed Turkey
D'Alo 2004 193 (107/86) 273(147/126) 193 AML Healthy controls (PB) 62(19–87)/60(19–90) Caucasian Italy




Aydin-Sayitoglu 2006 249 (143/106) 140 (73/67) 50 adult AML;
44 pediatric AML
Healthy controls (PB) Adult:33(19–75); pediatric:
7.8(2–18)/28.7(16–59)
Caucasian Turkey
Bolufer 2007 443 (223/190) 454 (223/231) 302 AML Healthy controls (PB) 39.48(0.8-84)/38.38(1–85) Caucasian Spain
Jiang 2008 98 (NA) 120 (NA) 98 AML Healthy controls
(age-, sex-matched; PB)
NA(16–68)/NA(16–68) Asian China
Majumdar 2008 110 (70/40) 126 (54/72) 110 AML Healthy controls (PB) 35(4–81)/30(8–73) Asian India
Yamaguti 2009 133 (70/63) 133 (70/63) 133 AML Healthy controls (PB) 47(11–89)/53(25–60) Mixed Brazil
Bonaventure 2012 493 (266/227) 549 (292/257) 51 AML Healthy controls
(age-, gender-matched; PB)
NA(0–15)/NA(0–15) Caucasian France
Kim 2012 415 (223/192) 1700 (821/879) 415 AML Healthy controls (PB) 50.5(15–86)/52.2(20–74) Asian Korea
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tion were not offered; third, reviews and duplicated pub-
lications. After deliberate searching, we reviewed all
papers in accordance with the criteria defined above for
further analysis.
Data extraction
Data were carefully extracted from all eligible publica-
tions independently by two of the authors according to
the inclusion criteria mentioned above. For conflicting
evaluations, an agreement was reached following a dis-
cussion. If a consensus could not be reached, another
author was consulted to resolve the dispute and then a
final decision was made by the majority of the votes.
The extracted information was entered into a database.
Statistical analysis
The odds ratio (OR) of CYP1A1 MspI polymorphisms
and AML risk was estimated for each study. The pooled
ORs were performed for an allelic contrast (C allele ver-
sus T allele), a homozygote comparison (CC versus TT)
and a dominant model (CC+TC versus TT). For detec-
tion of any possible sample size biases, the OR and its
95% confidence interval (CI) to each study was plotted
against the number of participants respectively. A Chi-
square based Q statistic test was performed to assess
heterogeneity. If the result of the Q-test was P >0.1,
ORs were pooled according to the fixed-effect model
(Mantel-Haenszel); otherwise, the random-effect model
(DerSimonian and laird) was used. The significance of
the pooled ORs was determined by Z-test. The Hardy-
Weinberg equilibrium (HWE) was assessed by Fisher’s
exact test. Publication bias was assessed by visual inspec-
tion of funnel plots [9], in which the standard error of
log (OR) of each study was plotted against its log (OR).
An asymmetric plot indicates a possible publication bias.
The symmetry of the funnel plot was further evaluatedTable 2 Distribution of CYP1A1 MspI genotypes among acute
meta-analysis
First Author Year Genotyping method Case
CC TC
Balta 2003 PCR-RFLP 0 6
D'Alo 2004 PCR-RFLP 0 17
Clavel 2005 PCR-RFLP 0 5
Aydin-Sayitoglu 2006 PCR-RFLP 5 24
Bolufer 2007 Real-time PCR 0 31
Jiang 2008 PCR-RFLP 19 50
Majumdar 2008 PCR-RFLP 30 39
Yamaguti 2009 PCR-RFLP 9 59
Bonaventure 2012 Infinium platform 2 7
Kim 2012 PCR-RFLP 61 219by Egger’s linear regression test [10]. Statistical analysis
was undertaken using the program STATA 11.0 software
(Stata Corporation, Texas).Results
Study characteristics
Relevant publications were retrieved and screened ori-
ginally. A total of seventy-eight publications were identi-
fied, of which sixty irrelevant papers were excluded. As
shown in Figure 1, eighteen publications were prelimin-
ary eligible, of which four publications not being case–
control studies [11-14] and one article not presenting
sufficient information [15] were discarded. Next, two
studies [16,17] whose genetic distributions of the control
groups exhibited evident deviation from HWE were
excluded. Then, one duplicate publication [18] which
concerned the same research with one of the included
studies [19] was further excluded. Lastly, ten case–
control studies were selected for data extraction [19-28].
Of the selected publications, one was written in Chin-
ese [24] while the remaining nine were in English. The
relevant information was listed in Table 1. According to
this table, the first author and the number and charac-
teristics of cases and controls for each study as well as
other necessary information are presented.
There were four groups of Caucasians [19,21,25,26],
three of Asians [20,23,24] and three of mixed races
[22,27,28] in this meta-analysis. As for age groups, there
were seven groups of adult AML [19,20,22-26] and four
groups of childhood AML [21,25,27,28] in this study.
Noticeably, the study conducted by Aydin-Sayitoglu et
al. . . [25] involved two subgroups regarding adult AML
and childhood AML, respectively.
The distributions of CYP1A1 MspI genotype as well
as the genotyping methods of the included studies are
presented in Table 2. The genetic distributions of themyeloid leukemia cases and controls included in the
s Controls HWE (control)
TT CC TC TT Chi-squre P
20 7 35 103 2.862 > 0.05
161 0 42 226 1.937 > 0.05
22 0 24 81 1.748 > 0.05
65 4 30 106 1.049 > 0.05
168 2 84 317 2.062 > 0.05
29 26 50 44 2.610 > 0.05
41 9 51 66 0.040 > 0.05
65 6 32 95 2.199 > 0.05
41 7 87 454 1.435 > 0.05
135 263 801 636 0.170 > 0.05
Table 3 Main results of the pooled data in the meta-analysis
No. (cases/controls) C allele vs T allele CC vs TT (CC+ TC) vs TT
OR (95%CI) P (OR) P (Q-test) OR (95%CI) P (OR) P (Q-test) OR (95%CI) P (OR) P (Q-test)
Total 1330/3688 1.13 (0.87-.1.48) 0.349 0.000 1.72 (0.99-3.01) 0.055 0.026 1.16 (0.86-1.55) 0.326 0.002
Ethnicity
Caucasian 521/1359 0.90 (0.59-.1.37) 0.629 0.062 2.02 (0.76-5.36) 0.160 0.462 0.85 (0.57-1.26) 0.415 0.127
Asian 623/1946 1.35 (0.90-2.02) 0.150 0.004 1.77 (0.72-4.35) 0.214 0.002 1.33 (1.09-1.62) 0.004 0.382
Mixed 186/383 1.11 (0.48-2.55) 0.807 0.029 1.40 (0.28-6.90) 0.681 0.227 1.24 (0.48-3.22) 0.654 0.021
Age groups
Adult AML 1183/2890 1.21 (0.88-1.66) 0.244 0.000 1.76 (0.94-3.30) 0.078 0.015 1.26 (0.88-1.81) 0.213 0.000
Childhood AML 147/938 1.02 (0.69-1.49) 0.938 0.620 1.78 (0.60-5.32) 0.299 0.376 0.97 (0.63-1.49) 0.877 0.856
AML, acute myeloid leukemia.
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with HWE.Test of heterogeneity
As shown in Table 3, we analyzed the heterogeneity for
the allelic contrast (C allele versus T allele), homozygote
comparison (CC versus TT) and dominant model (CC+
TC versus TT), respectively. Evident heterogeneities
were observed for the overall data in the three gen-
etic comparisons (C allele versus T allele: P = 0.000 for
Q-test; CC versus TT: P = 0.026 for Q-test; CC+TC ver-
sus TT: P = 0.002 for Q-test). Additionally, I-square value
is another index for the heterogeneity test [29], with
value less than 25% indicating low, 25% to 50% indicat-
ing moderate, and greater than 50% indicating high het-
erogeneity. The I-square values were 71.7%, 55.9% andFigure 2 Meta-analysis for the association of acute myeloid leukemia
(CC+ TC versus TT).65.5 for the overall data of the allelic contrast, homozy-
gote comparison and dominant model, respectively, indi-
cating marked heterogeneities between the studies.
Hence, the random-effect models were utilized. However,
when subgroup analyses regarding ethnicity and age
groups were further conducted, we found loss of hetero-
geneities in the subgroups regarding Caucasians and
childhood AML, respectively.Meta-analysis results
The main results of the meta-analysis were listed in
Table 3. For the overall data containing 1330 cases
and 3688 controls, the pooled ORs for the allelic con-
trast, homozygote comparison and dominant model
were 1.13 (95%CI = 0.87-1.48), 1.72 (95%CI = 0.99-3.01)
and 1.16 (95%CI = 0.86-1.55), respectively, indicating thatrisk with CYP1A1 MspI polymorphism for the overall data
Figure 3 Meta-analysis for the association of acute myeloid leukemia risk with CYP1A1 MspI polymorphism (CC+ TC versus TT;
stratified by ethnicity).
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ation with AML risk (Figure 2).
However, in subgroup analysis according to ethnicity,
increased risk was shown among Asians (OR = 1.33;
95%CI = 1.09-1.62; P = 0.382 for heterogeneity) under
the dominant model, but not the allele contrast or
homozygote comparison models. No increased riskFigure 4 Meta-analysis for the association of acute myeloid leukemia
(CC+ TC versus TT). AML, acute myeloid leukemia.could be observed among Caucasians or mixed races
under the three genetic models. The data indicated that
Asians who carry variant C allele might have increased
AML risk relative to those who harbor wild type TT
alleles. (Figure 3).
In subgroup analyses regarding age groups, no
increased risk was found among either the childhoodrisk with CYP1A1 MspI polymorphism stratified by age groups
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three genetic comparisons (Figure 4).
Sensitivity analysis
When the effect-models were changed, the significance
of the overall data for the two comparisons, respectively,
was not statistically altered (data not shown). Then, one-
way sensitivity analysis [30] was carried out to assess the
stability of the meta-analysis. The statistical significance
of the results was not changed when any single study
was omitted (data not shown), indicating the credibility
of the results.
Bias diagnostics
Funnel plots were created to detect possible publication
bias. Then, Egger’s linear regression tests were used to
assess the symmetries of the plots. The funnel plotsFigure 5 Publication bias tests for the overall data (CC+ TC versus TTappeared to be symmetrical for the overall data
(Figure 5a). Moreover, results of the Egger’s tests also
indicated that the potential publication bias was not
evident (Figure 5b) (C allele versus T allele: t = −0.20,
P> 0.05; CC versus TT: t = 0.66, P >0.05; CC + TC ver-
sus TT: t = −0.50, P >0.05).
Discussion
For the overall data, the results showed that CYP1A1
MspI polymorphism might not have a significant correl-
ation with AML risk. Moreover, in subgroup analyses
stratified by ethnicity, the data suggested an excess AML
risk among Asians but not Caucasians or mixed races.
Previously, several meta-analyses have been devoted to
the association of CYP1A1 MspI polymorphism with
other cancer risk. Nevertheless, the results were conflict-
ing. CYP1A1 MspI genetic variations have been). (a): Funnel plot; (b) Egger’s linear regression test.
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prostate cancer and laryngeal cancer [31-34]. However,
negligible relations between polymorphic CYP1A1 MspI
and gastric cancer, colorectal cancer, breast cancer and
esophageal cancer risks have been found [35-38]. There-
fore, polymorphism of CYP1A1 MspI might play differ-
ent roles in different cancers.
As for leukemia, a recent meta-analysis by Zhang
et al. . . [39] regarding the relations of CYP1A1 MspI
polymorphism with childhood acute leukemia failed to
suggest a significant association regarding childhood
ANLL (AML), in line with the present study. However, in
the study by Zhang et al. [39], only two studies regarding
childhood AML were selected [27,28]. Another two
important studies that met the inclusion criteria were
ignored [21,25]. In the present meta-analysis, a total of
ten studies concerning childhood AML as well as adult
AML were included, which statistically increased power
to assess the associations.
In subgroup analysis according to ethnicity, signific-
ant increased risk was found among Asians, but not
Caucasians and mixed races. Notably, this association
could be only observed in the dominant model but not
the allele contrast and homozygote comparison models,
indicating that Asians who bear variant C allele of
CYP1A1 MspI polymorphism might have an excess
AML risk compared with those who carry wild type TT
alleles. Possible racial differences in presentation, treat-
ment patterns and survival with respect to AML might
exist [40]. The difference might be owing to a possible
role of ethnic differences in genetic backgrounds and the
environment they lived in. However, the differences
might be due to chance because the limited number
of included studies and small sample sizes might give
rise to insufficient statistical power for detection of a
minor effect. Thus, the results should be interpreted
with caution because undulated risk estimation might be
obtained. Further studies regarding different ethnicities
with large sample sizes are needed to clarify this issue.
In the subgroup analysis stratified by age groups, no
increased risk was shown among either the childhood
AML or the adult AML subgroups. Evidence indicates
that the etiologies of childhood AML and adult AML
might be different [41]. Moreover, host genetic differ-
ences between the two age groups might exist [42].
Therefore, the possible differences regarding CYP1A1
MspI polymorphism between the two age groups should
be noted in further investigations. However, the data
indicated that the potential difference was not evident in
the present meta-analysis.
The overall data were not stratified by source of con-
trols because all studies concerned the population-based
controls, except for one study with limited sample sizes
[28]. Hospital-based controls might not be always trulyrepresentative of the general population. In addition, the
population-based controls in several studies were not
strictly matched to the cases. Thus, any selection bias
might exist. Future studies using proper control partici-
pants with strict matching criteria and large sample sizes
are important for reducing such selection bias.
In the present meta-analysis, evident between-study
heterogeneities for the overall data were observed for
the three comparisons, respectively, and thus, the
random-effect models were utilized. In the subgroup
analyses, loss of heterogeneities was also found in the
subgroups regarding Caucasian and childhood AML,
respectively. Though we tried to minimize the possibility
of encountering heterogeneity problems by conducting
a careful search of the literature and using rigorous
criteria for data pooling, evident heterogeneities still existed
in some of the comparisons. Therefore, heterogeneities
might be multifactoral. In addition to ethnicity and age
groups, other factors such as gender, source of controls,
histological types and prevalence of lifestyle factors
might also yield the heterogeneities.
Several limitations should be concerned in the present
meta-analysis. First, the primary articles only provided
data about Caucasians, Asians and mixed races. Detailed
information regarding other ethnicities such as African
should be concerned. Second, subgroup analyses regarding
gender and other factors such as smoking, drinking and
radiation exposure have not been conducted in the present
study because relevant information was insufficient in the
primary articles. Third, only studies written in English and
Chinese were included in this meta-analysis. Any selection
bias should be noted. Furthermore, although the meta-
analysis in this study is suggestive, high heterogeneity and
lack of significant association in any genetic model among
Caucasian and Mixed subgroups or age subgroups
observed in this study could also originate from the nature
of AML as a genetically heterogeneous disease and further
assessment on the relationship between CYP1A1 MspI
polymorphism and risk of AML subtypes might provide
more instructive information. Additionally, gene-gene and
gene-environment interactions should also be considered
in the further investigations.
In summary, the results of the present meta-analysis
suggest that variant C allele of CYP1A1 MspI poly-
morphism might have an association with increased
AML risk among Asians. Further investigations are
needed to confirm the conclusions.
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